Skip to main content
Signal8
Launch Terminal

Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

NASDAQ:TVTXHealthcare
-0.36%$50.39
AH$50.39+0.00%vs close
Mkt Cap$4.75B
Float90.15M
O/S94.26M
Vol
$ Vol
RVOL
Inst Own-
SI12.1%
Earnings
Dilution
Travere Therapeutics, Inc. logoNASDAQ:TVTX$50.39-0.36%
Phase Distribution
14 lead-sponsored trials·5 active·8 completed
Phase 11
Phase 1/21
Phase 23
Phase 35
Phase 41
Not applicable3
(5 more as collaborator)
Status Overview
Recruiting4
Active, not recruiting1
Completed8
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Active, not recruiting

    Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

    Sparsentan

    Proteinuria, Immunoglobulin A (IgA) Nephropathy +2

    Enrollment
    20
    Start
    Oct 2025
    Primary Completion
    Mar 2027est.
    Completion
    May 2027est.
    NCT07219121
  • Phase 3
    Terminated

    Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants

    Fosmetpantotenate, Placebo

    Pantothenate Kinase-Associated Neurodegeneration

    Enrollment
    84
    Start
    Jul 2017
    Primary Completion
    Dec 2019
    Completion
    Dec 2019
    NCT03041116
  • Phase 3
    Completed

    Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

    sparsentan, Irbesartan

    Focal Segmental Glomerulosclerosis

    Enrollment
    371
    Start
    Apr 2018
    Primary Completion
    Mar 2023
    Completion
    Mar 2026
    NCT03493685
  • Phase 3
    Completed

    A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

    sparsentan, irbesartan

    Immunoglobulin A Nephropathy

    Enrollment
    406
    Start
    Dec 2018
    Primary Completion
    Aug 2023
    Completion
    Aug 2026
    NCT03762850
  • Phase 3
    Recruiting

    Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment

    Pegtibatinase

    Homocystinuria

    Enrollment
    70
    Start
    Dec 2023
    Primary Completion
    Aug 2027est.
    Completion
    Sep 2027est.
    NCT06247085
  • Phase 3
    Enrolling by invitation

    A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)

    Pegtibatinase

    Homocystinuria

    Enrollment
    100
    Start
    Apr 2024
    Primary Completion
    Aug 2030est.
    Completion
    Aug 2030est.
    NCT06431893
  • Phase 2
    Completed

    Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

    RE-021 (Sparsentan), Irbesartan

    Focal Segmental Glomerulosclerosis

    Enrollment
    109
    Start
    Mar 2014
    Primary Completion
    Jun 2016
    Completion
    Mar 2024
    NCT01613118
  • Phase 2
    Recruiting

    Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

    Sparsentan, Sparsentan

    Focal Segmental Glomerulosclerosis, Minimal Change Disease +3

    Enrollment
    67
    Start
    Aug 2021
    Primary Completion
    Mar 2027est.
    Completion
    Apr 2027est.
    NCT05003986
  • Phase 2
    Completed

    A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

    Sparsentan

    Immunoglobulin A Nephropathy

    Enrollment
    48
    Start
    May 2023
    Primary Completion
    Oct 2024
    Completion
    Oct 2024
    NCT05856760
  • Phase 1/2
    Recruiting

    Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

    Pegtibatinase, Placebo

    Homocystinuria

    Enrollment
    39
    Start
    Jan 2019
    Primary Completion
    Jul 2027est.
    Completion
    Jul 2027est.
    NCT03406611
  • Phase 1
    Completed

    Study to Evaluate the Pharmacokinetics of Oral Sparsentan Suspension

    RE-021, sparsentan

    Healthy Subjects

    Enrollment
    47
    Start
    Jun 2020
    Primary Completion
    Nov 2020
    Completion
    Nov 2020
    NCT05562362
  • Observational
    Completed

    Cerebrotendinous Xanthomatosis (CTX) Prevalence Study

    -

    Cerebrotendinous Xanthomatosis (CTX)

    Enrollment
    442
    Start
    Sep 2015
    Primary Completion
    Feb 2021
    Completion
    Feb 2021
    NCT02638220
  • Observational
    Completed

    Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)

    -

    Homocystinuria Due to CBS Deficiency

    Enrollment
    110
    Start
    Jan 2017
    Primary Completion
    Jul 2026
    Completion
    Jul 2026
    NCT02998710
  • Observational
    Completed

    Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)

    -

    Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy

    Enrollment
    487
    Start
    Feb 2022
    Primary Completion
    Oct 2023
    Completion
    Oct 2023
    NCT05200871
Search ClinicalTrials.gov for “Travere Therapeutics”